When Will Pfizer Be Ready For Its Next Big (Or Small) Move?
This article was originally published in The Pink Sheet Daily
A year after its failed takeover bid for AstraZeneca, Pfizer Inc. continues to face questions about whether it will pursue another large-scale merger, and how it is preparing for a potential spin off.
You may also be interested in...
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
The deadline is approaching for submissions to the 2023 Citeline Awards; gain recognition for your clinical research team, real world evidence project, diversity and inclusion efforts, and more.
Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.